| 2026-03-12 |
详情>>
股本变动：
变动后总股本958.63万股
|
| 2026-03-12 |
详情>>
业绩披露：
2025年年报每股收益0.64美元,归母净利润569.60万美元,同比去年增长4088.24%
|
| 2026-03-12 |
财报披露：
美东时间 2026-03-12 盘前发布财报
|
| 2026-02-15 |
详情>>
内部人交易：
DesRosier Thomas等共交易5笔
|
| 2026-02-12 |
复牌提示：
2026-02-12 06:55:00 停牌，复牌日期 2026-02-12 07:30:00
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.41美元,归母净利润2103.10万美元,同比去年增长33.34%
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益1.47美元,归母净利润1282.70万美元,同比去年增长117.57%
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益3.76美元,归母净利润3268.20万美元,同比去年增长181.43%
|
| 2025-04-21 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2025-03-13 |
股东大会：
将于2025-04-10召开股东大会
会议内容 ▼▲
- 1.To elect Dennis A. Ausiello, M.D., Willard H. Dere, M.D., and Eric D. Shaff as Class I Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To approve the Seres Therapeutics, Inc. 2025 Incentive Award Plan as an amendment and restatement of the Seres Therapeutics, Inc. 2015 Incentive Award Plan, which is scheduled to expire in 2025;
5.To approve amendments to our Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to effect a reverse stock split;
6.To approve amendments to our Certificate of Incorporation to clarify voting requirements to amend the number of shares of authorized common stock and preferred stock;
7.To approve amendments to our Certificate of Incorporation to eliminate supermajority voting requirements;
8.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposals 5, 6 or 7;
9.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2025-03-13 |
详情>>
业绩披露：
2022年年报每股收益-2.31美元,归母净利润-2.5亿美元,同比去年增长-281.46%
|
| 2025-03-13 |
详情>>
业绩披露：
2024年年报每股收益0.00美元,归母净利润13.60万美元,同比去年增长100.12%
|
| 2024-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.57美元,归母净利润-7247.6万美元,同比去年增长60.04%
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.11美元,归母净利润1577.30万美元,同比去年增长121.76%
|
| 2024-08-26 |
股东大会：
将于2024-09-26召开股东大会
会议内容 ▼▲
- 1.To approve the proposed sale (the “Transaction”) of Seres’ VOWST microbiome therapeutic business (the “VOWST Business”) to Société des Produits Nestlé S.A. (“SPN”) pursuant to the terms of the Asset Purchase Agreement, dated as of August 5, 2024 (the “Purchase Agreement”), by and between Seres and SPN (the “Transaction Proposal”);
2.To approve, on a non-binding, advisory basis, certain compensation that will or may become payable to our named executive officers in connection with the Transaction (the “Compensation Proposal”);
3.To approve the adjournment of the special meeting to a later date or dates, if necessary, to solicit additional proxies if there are insufficient votes to adopt the Transaction Proposal at the time of the special meeting (the “Adjournment Proposal”).
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.49美元,归母净利润-7300.3万美元,同比去年增长-196.5%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.27美元,归母净利润-4013.3万美元,同比去年增长43.61%
|
| 2024-03-05 |
股东大会：
将于2024-04-04召开股东大会
会议内容 ▼▲
- 1.To elect Paul R. Biondi and Kurt C. Graves as Class III Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock, par value $0.001 per share (our "Common Stock") from 240,000,000 to 360,000,000;
5.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4;
6.If properly presented at the Annual Meeting, to vote upon a stockholder proposal on simple majority vote;
7.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-0.89美元,归母净利润-1.14亿美元,同比去年增长54.54%
|
| 2023-04-25 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.To elect Stephen A. Berenson, Richard N. Kender, and Claire M. Fraser, Ph.D. as Class II Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock, par value $0.001 per share (our "Common Stock") from 200,000,000 to 240,000,000;
5.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4;
6.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2022-04-29 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.To elect Dennis A. Ausiello, M.D., Willard H. Dere, M.D., and Eric D. Shaff as Class I Directors to serve until the 2025 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.To elect Gregory Behar, Paul R. Biondi, and Kurt C. Graves as Class III Directors to serve until the 2024 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2020-04-30 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.To elect Stephen A. Berenson, Richard N. Kender, and Meryl S. Zausner as Class II Directors to serve until the 2023 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020; 3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2019-04-30 |
股东大会：
将于2019-06-13召开股东大会
会议内容 ▼▲
- 1.To elect Dennis A. Ausiello, M.D., Willard H. Dere, M.D., Roger J. Pomerantz, M.D. and Eric D. Shaff as Class I Directors to serve until the 2022 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019; 3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2018-04-30 |
股东大会：
将于2018-06-26召开股东大会
会议内容 ▼▲
- 1.To elect Noubar B. Afeyan, Ph.D., Grégory Behar, and Kurt C. Graves as Class III Directors to serve until the 2021 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018; 3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2017-05-01 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1. To elect Richard N. Kender and Lorence H. Kim, M.D. as Class II Directors to serve until the 2020 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|
| 2016-04-28 |
股东大会：
将于2016-06-15召开股东大会
会议内容 ▼▲
- 1.To elect Dennis A. Ausiello, M.D. and Roger J. Pomerantz, M.D. as Class I Directors to serve until the 2019 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting.
|